公开(公告)号：US20220090133A1

公开(公告)日：2022-03-24

申请号：US17435768

申请日：2020-03-03

Applicant: AMGEN INC.

Inventor： Jason James DEVOSS ,  Walter Hans MEISEN ,  Christine Elaine TINBERG ,  Keegan COOKE ,  Achim Klaus MOESTA

IPC: C12N15/86 ,  C12N7/00 ,  C07K14/54 ,  C07K14/71 ,  A61P35/00 ,  A61K38/20 ,  A61K38/17

Abstract: The present invention relates to the use of oncolytic viruses (e.g., modified HSV-1 viruses) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses.

公开(公告)号：US20200009204A1

公开(公告)日：2020-01-09

申请号：US16493376

申请日：2018-03-14

Applicant: AMGEN INC.

Inventor： Pedro J. BELTRAN ,  Courtney BEERS ,  Keegan COOKE

IPC: A61K35/763 ,  C07K16/28 ,  A61P35/00

Abstract: The present invention relates to the use of oncolytic viruses (e.g., talimogene laherparepvec), either alone or in combination with immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD-1, and anti-PD-L1 compounds such an antibodies) for the treatment of various types of cancer. In addition, the present invention relates to compositions and kits relating to such uses of oncolytic viruses, either alone or in combination with immune checkpoint inhibitors.